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and (4) normal without heart instrumentation plus Carvedilol(n=6). In 
groups 2 and 3, after baseline measurements had been obtained, rapid 
left ventricular (LV) pacing was initiated at 210 bpm for 3 weeks, fol- 
lowed by an additional week of pacing at 240 bpm with an external 
pacemaker. Carvedilol, was begun 2 weeks after initiation of pacing and 
continued for 2 weeks. Carvedilol was begun 2 weeks after baseline mea- 
surement for the control dogs with heart instrumentation. SR membranes 
were prepared from canine ventricular tissue, Protein concentration was 
measured by Bradford assay. 
Results: Here, we show that systemic oral administration of Carvedilol 
reverses protein kinase A hyperphosphorylafion of RyR2, restores the 
stoichiometry of the RyR2 macromolecular complex, and normalizes 
single-channel function in a canine model of heart failure. 
Conclusions: These results may, in part, explain the improved cardiac 
function observed in heart failure patients treated with Carvedilol. 
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Aims: Our previous studies revealed that cardioplegia-induced cardiac 
arrest (CCA) under cardiopulmonary bypass (CPB) could decrease car- 
diomyocytic nitric oxide (NO) and increase apoptosis. We hypothesized 
that pre-treatment with bradykinin would improve the p rone  of antiapop- 
totic proteins and inhibit cardiomyocytic apoptosis. 
Methods: New Zealand white rabbits (10 in each group, each 2.5-3.5 kg) 
received total CPB. Rabbits were weaned from CPB and reperfused for 
4 hours before the hearts were harvested. Blood was sampled at various 
time points. Bradykinin and/or NO agonists or inhibitor was infused sys- 
temicaJly 30 minutes before beginning of the extracorporeaJ circulation 
and continued through the whole procedure. The ascending aorta was 
cross-clamped for 60 minutes while cold crystaJloid cardioplegic solu- 
tion was intermittently infused into the aortic root every 20 minutes. The 
myocardia of the reperfused hearts and control hearts were harvested and 
studied for evidence of apoptosis, ischemia/repeffusion-induced proin- 
flammatory gene expression and inflammatory cytokine production by 
cardiomyocytes. 
Results: Pretreatment of the cardiomyocytes with bradykinin could pre- 
vent the ischemia/repeffusion-induced inflammatory and apoptotic ef- 
fects, which could be reversed with NO synthase inhibitor. Bradykinin 
antagonist could worsen the inflammatory and apoptotic responses of 
cardiomyocytes, which could be reversed with exogenous NO donor. 
Restoring NO concentration after CCA under CPB with bradykinin could 
modulate the (1) nuclear translocation of NF-KB, (2) iNOS mRNA ex- 
pression, (3) cytochrome c production, and (4) occurrence of apoptosis. 
Conclusions: CCA under CPB can decrease endogenous NO production, 
which can be restored with bradykinin supplementation via NO-mediated 
pathway. Exogenous bradykinin can ameliorate the myocardial inflam- 
matory response by inhibition of NF-KB translocation, inflammatory gene 
expression, iNOS expression, and cytochrome c production. 
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Background: The aim of the study was to assess early and long-term 
results of myocardial revascularization in patients with low left ejec- 
tion fraction (LVEF) below 35% who underwent either elective coronary 
artery bypass grafting (CABG) or elective percutaneus transluminaJ coro- 
nary angioplasty (PTCA). 
Material and methods: The study group comprised 176 patients (103 
after standard CABG and 73 following PTCA) hospitalized in the Depart- 
ment of Cardiac Surgery, Medical University of Lodz, Poland between 
1999 and 2004. All patients had preoperative coronary angiography and 
echocardiography at rest. A postoperative control echocardiography was 
done twice: between 5th and 7th day and 6th and 12th month after the 
procedure. The following parameters were then assessed: general LVEF, 
regional systolic abnormalities, left ventricular and left atrial dimension, 
left ventricular diastolic function and secondary mitraJ regurgitation (if 
present). 
Results: The patients from both groups did not differ in the respect of 
sex and age, however diabetes was more frequent in the surgical group. 
A complete revascularization was achieved in 91 patients treated with 
CABG (88%) and in 33 patients treated with PTCA (45%). Significantly 
more early in-hospitaJ deaths were observed in surgical group compared 
with PTCA group (15 patients [14.5%] vs. 3 patients [0.41%], respec- 
tively). In postoperative echocardiography, slightly bigger improvement 
in LVEF, higher reduction in a quantity of myocardial segment with 
systolic abnormalities and decrease in left ventricular dimension were 
observed in the surgical group, but the results were not statistically signif- 
icant. Also restrictive abnormalities of left ventricular diastolic function 
were predictors of worse early outcome in both groups. During follow- 
up both groups did not differ significantly when incidence of strokes and 
myocardial infarctions was analyzed. 
Conclusions: (1). Complete surgical revascularization of myocardial in 
patients with heart failure yields with better results than PTCA as far as 
left ventricular systolic function was concerned. (2). Percutaneus meth- 
ods of revascularization patients with low LVEF yield with lower in- 
hospital mortality but involve more frequent need for repeat revascu- 
larization. (3). Restrictive left ventricular diastolic abnormalities were 
connected with worse prognosis in both groups. (4). Progress in surgical 
and percutaneus methods of revascularizafion gives a better chance for 
survival in patients with significant lesion of left ventricle - a population 
of the highest risk. 
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Background: Advances in the field of mechanical circulatory support 
have focused on the development of smaller, quieter left ventricular as- 
sist devices (LVAD) that have improved durability and the potential for 
improved quality of life while maintaining the hemodynamic benefits of 
the first generation pulsatile pumps. We report the results of the Heart- 
Mate II ® (HMII) pilot study in which a 400 gm axial flow LVAD was 
used to support patients (pts) with NYHA Class IV heart failure (HF) as 
a bridge to cardiac transplantation. 
Methods: The HMII was implanted in 46 pts (36% female) with a me- 
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dian age of 40 yrs (range:14-69) and a median BSA in women of 1.65 
(range: 1.40-2.20) and in men 2.01 (range: 1.61-2.28). Most pts had either 
ischemic (35%) or idiopathic (40%) cardiomyopathy. Pre-operatively pts 
were systemically hypotensive (mean systolic BP=974-12 mmHg) with 
elevated tilling pressures (rt atrial pressure=124-7 mmHg; pulmonary 
capillary wedge pressure=244-7 mmHg) despite treatment with positive 
inotropic agents (97%) or an intraaortic balloon pump (22%). The HMII 
was implanted via an inflow cannula placed in the left ventricular (LV) 
apex and an outflow graft attached to the ascending aorta. Echocardiogra- 
phy was used to determine the appropriate pump speed using reduction in 
LV size, displacement of the septum toward the LV free wall and opening 
of the aortic valve. 
Results: The cardiac index improved from 2.04-0.5 to an estimated pump 
flow index 2.94-0.5 L/min/m 2 at one week at an average pump speed of 
92164-368 rpm. The median duration of mechanical support was 118 
days (longest= 2 yrs; 9 pts> 1 yr), representing 21 pt-years on the device. 
There were no pump failures and one pump was replaced following acci- 
dental trauma. Common adverse events included perioperative bleeding 
(38%) and driveline infection (11%). Two pts had a stroke and there was 
1 TIA. Of the 46 pts, 32 (70%) survived (19 transplanted, 1 recovered, 
12 ongoing) and 30% died on the device, most within 30 days of mul- 
tisystem organ failure. Three months following implant, improvements 
were seen in subma, ximaJ exercise performance (52% of pts had > 200 
meter increase in 6 minute walk distance), 71% of pts had NYHA Class 
I-II symptoms, and 76% reported their health as good, very good or ex- 
cellent. 154 pts have subsequently been enrolled in the phase II trial for 
transplant and non-transplant candidates. 
Conclusions: The HMII a, xiaJ flow LVAD is reliable and restores hemo- 
dynamics with minimal adverse events in pts with advanced HF while 
improving functional status, exercise performance, and quality of life. 
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Background: Temporary ventricular assist devices (VADs) are used in 
0.2%-1.2% of all cardiac surgical cases. The hospital discharge rate with 
temporary VADs as "bridge to recovery" in the post-cardiotomy setting 
remains low. This study evaluates a recently developed VAD (Tandem- 
Heart pVAD, Cardiac Assist,Pittsburg) in this setting. 
Methods: Between August 2001 and August 2004, 14 patients (0,6% of 
all cardiac surgical cases) were supported by VADs. Eleven of them un- 
derwent insertion of the TandemHeart. They were all male, with a mean 
age of 65.6 years (range 48-87), a mean LVEF of 26.8%4-13.6 (range 
10-55), a median Euroscore of 9 (range 6-17). In 7 of 11 patients acute 
heart failure occurred as perioperative decompensation of preexisting end 
stage chronic heart failure. The mean LVEF in this group was 18.6%4-5.5 
(range 10-25). Five of them underwent CABG and endoventriculoplasty 
procedures, one AVR and undersized mitraJ annuloplasty, and one Redo 
MVR of a thrombosed prosthetic valve. Four of the 11 patients with acute 
heart failure due to acute coronary syndromes, underwent CABG as sal- 
vage (n=2) or as emergency (n=2) procedures. In all patients with acute 
ischemia and in one patient with preexisting heart failure TandemHeart 
insertion was preceded by IABP insertion. The major indication for VAD 
insertion was failure to wean from CPB (9 patients, intraoperative inser- 
tion by "open percutaneous technique", or by direct cannulation). Other 
indications were preoperative decompensation of chronic heart failure (1 
patient, preoperative percutaneous insertion) and postcardiotomy sudden 
cardiac arrest (1 patient, postoperative direct insertion). 
Results: The mean duration of support was 884-98.4 hours (range 0.5- 
264 hrs). The mean pump flow was 3.094-1L/rain (range 2.1-6). Eight 
of 11 patients were successfully weaned (72.72%) from the device and 
6 of 11 patients were discharged from hospital (54.54%). The major 
complication was bleeding, noted mainly in patients receiving anticoag- 
ulation preoperatively. No device malfunctioning was noted. Survival in 
1 and 4 years was 45.45% and 36.36% respectively. All survivors are in 
functional class I or II. 
Conclusion: Safety of the TandemHeart in cardiac surgery was demon- 
strated by this study. Support led to successful weaning from CPB, in 
patients that would have probably died without assistance, resuscitation 
from refractory postoperative cardiac arrest, and preoperative hemody- 
namic stabilization in decompensated chronic heart failure. Device ap- 
plication was effective, with high weaning rate and satisfactory early and 
mid-term survival 
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In patients (pts) with advanced chronic heart failure (CHF) frequent hos- 
pitaJisations (HOSP) occur. Changes in volume (overload/depletion) are 
often misdiagnosed by clinical assessment. It has been hypothesized that 
continuous haemodynamic monitoring by implantable devices (IHM) de- 
tects increases in tilling pressures before the onset of symptoms and/or 
changes of physical signs, allowing earlier treatment and reducing mor- 
bidity. 
Aim: To verify how right heart (RH) hemodynamics changes in pts hos- 
pitaJised because of worsening CHF. 
Methods: 10 pts with advanced CHF and frequent cardiovascular HOSP 
were implanted with a device (Chronicle IHM - Medtronic Inc, Mine- 
sota) designed to record beat-to-beat right ventricular systolic (RVSP) 
and diastolic pressure (RVDP), pts activity and estimate of pulmonary 
artery diastolic pressure (ePAD). Pts during events activated high- 
resolution storage for 2 minutes by applying a magnet over the device; an 
external reference box recorder accounted for ambient barometric pres- 
sure; an external programmer read stored RV pressures. Hemodynamic 
changes were considered sustained when lasting >6 days. HOSP were 
characterized by presence/absence of inotropic infusion for treatment of 
low cardiac output state (LCO). 
Results: IHM data were available in 7 pts (soon after implantation 1 
pt died and 2 pts had a spoiled catheter). Among pts (males, mean age 
56.8 years) 6 were in the heart transplant list; aetiology of CHF was is- 
chemic heart disease; NYHA class IIIb-IV; echo left ventricular ejection 
fraction (LVEF) was 214-2%. RIt catheterisation findings were: systolic 
pulmonary artery pressure 594-8 mmHg, cardiac output 34-1.3 L/rain, 
fight atrial pressure 54-2 mmHg. During follow-up (154-7 months) 1 pt 
died, 2 were transplanted and 1 was implanted with a defibrillator. The to- 
tal number of HOSP during follow-up was 22 (in 68% inotropic support 
was required). In the week before HOSE the following hemodynamic 
changes were observed: RVSP was increased in 9 pts (41%), unchanged 
in 11 (50%) and decreased in 2 (9%); RVDP was increased in 18 pts 
(81%), unchanged in 3 (14%) and decreased in 1 (5%); ePAD was in- 
creased in 10 pts (45.5%), unchanged in 10 (45.5%) and decreased in 2 
(9%). 
Conclusions: In this small sample of pts with advanced CHF, an increase 
of RVSP and ePAD occurred only in about 40% of episodes of worsening 
CHF; noticeably, RVDP increased in 82% of cases. Information on RVSP 
cannot correctly be matched with clinical status in advanced CHF pts, 
as worsening of symptoms and HOSP are frequently related to LCO 
conditions. 
